1. I. P. Ashmarin, B. N. Nezavibat’ko, N. F. Myasoedov, et al., “The nootropic analog of adrenocorticotropin 4-10 – Semax (15 years of experience in its development and study),” Zh. Vyssh. Nerv. Deyat., 47, No. 3, 420–430 (1997).
2. T. A. Voronina and R. U. Ostrovskaya, “Methodological recommendations for studies of the nootropic activity of pharmacological substances,” in Handbook for the Experimental (preclinical) Study of New Pharmacological Substances), V. P. Fesenko (ed.), Remedium, Moscow (2000), pp. 153–158.
3. T. A. Voronina and S. B. Seredenin, “Methodological recommendations for the study of the tranquilizing (anxiolytic) activity of pharmacological substances,” ibid., pp. 126–130.
4. V. M. Getsova, N. V. Orlova, A. A. Folomkina, and V. N. Nezavibat’ko, “Effects of an ACTH analog on learning and memory processes in mice,” Zh. Vyssh. Nerv. Deyat., 38, No. 6, 1041–1047 (1988).
5. K. O. Eremin, V. S. Kudrin, I. A. Grivennikov, et al., “Effects of Semax on the dopaminergic and serotoninergic systems of the brain,” Dokl. Akad. Nauk., 394, No. 1, 130–132 (2004).